<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. ________)*
Cardiovascular Diagnostics Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $.001 par value per share
- --------------------------------------------------------------------------------
(Title of Class of Securities)
14160E106
- --------------------------------------------------------------------------------
(CUSIP Number)
Chiron Diagnostics Corporation, 63 North Street, Medfield, MA 02052
Attention: Senior Vice President and General Manager Critical Care
(508) 359-3818
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)
August 28, 1998
- --------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box./ /.
Note: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for the other parties to whom copies are to be
sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 8 pages
<PAGE>
SCHEDULE 13D
- --------------------------- ---------------------------
- --------------------------- ---------------------------
CUSIP NO. 14160E106 13D Page 2 of 8 Pages
----------------- ------- -------
- --------------------------- ---------------------------
- --------------------------- ---------------------------
- --------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Chiron Diagnostics Corporation
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) / /
(b) / /
- --------------------------------------------------------------------------------
3
SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS AF
- --------------------------------------------------------------------------------
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e) / /
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
NUMBER OF 7
SOLE VOTING POWER 600,000
SHARES
--------------------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER -0-
OWNED BY
--------------------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER 600,000
REPORTING
--------------------------------------------------------------
PERSON 10 SHARED DISPOSITIVE POWER -0-
WITH
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
600,000
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES / /
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
8.1%
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON CO
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO
ITEMS 1-7 (INCLUDING EXHIBITS) OF THE
SCHEDULE, AND THE SIGNATURE ATTESTATION.
Page 2 of 8 pages
<PAGE>
Item 1. Security and Issuer
-------------------
This statement on Schedule 13D relates to the common stock, $.001 par value
per share (the "Common Stock"), of Cardiovascular Diagnostics, Inc., a North
Carolina corporation (the "Issuer"), the principal executive offices of which
are located at 5301 Departure Drive, Raleigh, North Carolina 27604.
Item 2. Identity and Background
-----------------------
The Reporting Person is Chiron Diagnostics Corporation, a Delaware
Corporation (the "Company"). The Company's principal business and principal
office are located at 63 North Street, Medfield, Massachusetts 02052. The
Company's principal business is developing, manufacturing and marketing human
healthcare products for the diagnosis of disease.
The names, business addresses and principal occupations of the executive
officers and directors of the Company and the names, business addresses and
principal occupations of the executive officers and directors of Chiron
Corporation, a Delaware Corporation ("Chiron"), which wholly owns the Company
and whose principal address is 4560 Horton Street, Emeryville, CA 94608-0000,
are included on Schedule A attached hereto and incorporated herein by reference.
All of the executive officers and directors are believed to be citizens of the
United States.
The Company believes that, except as may be reported on Schedule A, each of
the Company, Chiron and their executive officers and directors has not, during
the last five years, been convicted in any criminal proceeding (excluding
traffic violations or similar misdemeanors) nor has been a party to any civil
proceeding of a judicial or administrative body of competent jurisdiction as a
result of which such person was or is subject to any judgment, decree or final
order enjoining further violations of, or prohibiting or mandating activities
subject to federal or state securities laws or finding any violations with
respect to such laws.
Item 3. Source and Amount of Funds or Other Consideration
-------------------------------------------------
The Company purchased 600,000 shares of the Common Stock (the "Shares")
from the Issuer in a private placement transaction for an aggregate purchase
price of $6,000,000, pursuant to a Common Stock Purchase Agreement dated
August 28, 1998 between the Company and the Issuer (the "Stock Purchase
Agreement"). The Company borrowed the funds to purchase the Shares from
Chiron pursuant to a revolving credit facility that Chiron makes available to
the Company.
Item 4. Purpose of Transaction
----------------------
Page 3 of 8 pages
<PAGE>
The Company purchased the Shares for investment. Pursuant to the Stock
Purchase Agreement, the Issuer is obligated to include in the slate of
nominees recommended by the Issuer's Board of Directors or management to
shareholders, for election as a director of the Issuer at the Issuer's next
meeting of shareholders, one person designated by the Company and reasonably
acceptable to the Issuer, in its sole discretion. Except as described in this
Item 4, the Company does not have any plan or proposal relating to, or which
would result in, any of the events described in (a) to (j) of the
instructions to Item 4.
Item 5. Interest in Securities of the Issuer
------------------------------------
(a) Beneficial Ownership by the Company of the Common Stock of the
Issuer:
Aggregate number of shares: 600,000
Percentage: 8.1%
<TABLE>
<CAPTION>
Number of Shares
----------------
<S> <C>
(b) Sole Voting Power: 600,000
Shared Voting Power: 0
Sole Dispositive Power: 600,000
Shared Dispositive Power: 0
</TABLE>
(c), (d)
and (e) Not applicable.
Item 6. Contracts, Arrangements, Understandings or Relationships with
-------------------------------------------------------------
Respect to Securities of the Issuer
-----------------------------------
None.
Item 7. Material to be Filed as Exhibits
--------------------------------
None.
Page 4 of 8 pages
<PAGE>
Signature
---------
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
CHIRON DIAGNOSTICS CORPORATION
Date: September 4, 1998 By: /s/ Gregory Maloblocki
-------------------------------------
Gregory Maloblocki
Corporate Counsel and Secretary
Page 5 of 8 pages
<PAGE>
SCHEDULE A
CHIRON DIAGNOSTICS CORPORATION
<TABLE>
<CAPTION>
Directors Title Business Address
--------- ----- ----------------
<S> <C> <C>
Richard W. Barker President 333 Coney Street, East Walpole, MA 02081
William G. Green Senior Vice President; 4560 Horton Street, Emeryville, CA 94608
General Counsel;
Assistant Secretary
Sean P. Lance President, Chief Executive 4560 Horton Street, Emeryville, CA 94608
Officer, Chiron Corporation
</TABLE>
<TABLE>
<CAPTION>
Executive Officers Title Business Address
------------------ ----- ----------------
<S> <C> <C>
Richard W. Barker President 333 Coney Street, East Walpole, MA 02081
Keith A. Costa Executive Vice President 333 Coney Street, East Walpole, MA 02081
Philip Tabbiner Senior Vice President; 333 Coney Street, East Walpole, MA 02081
President International
Group
Tom Finnerty Vice President 333 Coney Street, East Walpole, MA 02081
Jennifer Joiner Senior Vice President, 333 Coney Street, East Walpole, MA 02081
Immunodiagnostics
Robert L. Sullivan Senior Vice President; 333 Coney Street, East Walpole, MA 02081
Treasurer
Mickey Urdea Senior Vice President 4560 Horton Street, Emeryville, CA 94608
William C. Goodall Vice President 63 North Street, Medfield, MA 02052
Christopher M. Gleeson Senior Vice President 63 North Street, Medfield, MA 02052
Louis Riceberg Vice President 333 Coney Street, East Walpole, MA 02081
Gregory Maloblocki Secretary 63 North Street, Medfield, MA 02052
William G. Green Assistant Secretary 4560 Horton Street, Emeryville, CA 94608
Alisa Harbin Assistant Secretary 4560 Horton Street, Emeryville, CA 94608
Carolyn Mar Assistant Secretary 4560 Horton Street, Emeryville, CA 94608
Carolyn A. Mason Assistant Secretary 63 North Street, Medfield, MA 02052
Claudia Montante Assistant Secretary 4560 Horton Street, Emeryville, CA 94608
Arthur S. Morgenstern Assistant Secretary 63 North Street, Medfield, MA 02052
</TABLE>
CHIRON CORPORATION
<TABLE>
<CAPTION>
Directors Title Business Address
--------- ----- ----------------
<S> <C> <C>
Vaughn D. Bryson President, Life Science 4560 Horton Street, Emeryville, CA 94608
Advisor
Lewis W. Coleman Senior Managing Director; 4560 Horton Street, Emeryville, CA 94608
Co-Director Investment
Banking, Montgomery
Securities
</TABLE>
Page 6 of 8 pages
<PAGE>
<TABLE>
<S> <C> <C>
Pierre E. Douaze Head of Healthcare 4560 Horton Street, Emeryville, CA 94608
Division & Pharma Sector
Donald A. Glaser, Ph.D. Professor of Physics, 4560 Horton Street, Emeryville, CA 94608
Molecular Biology &
Neurobiology, University of
California at Berkeley
Paul L. Herrling, Ph.D. Head of Research, 4560 Horton Street, Emeryville, CA 94608
Novartis Pharma AG
Alex Krauer, Ph.D. Chairman, Novartis AG 4560 Horton Street, Emeryville, CA 94608
Sean P. Lance President, Chief Executive 4560 Horton Street, Emeryville, CA 94608
Officer
Edward E. Penhoet, Ph.D. Vice Chairman 4560 Horton Street, Emeryville, CA 94608
William J. Rutter, Ph.D. Chairman 4560 Horton Street, Emeryville, CA 94608
Jack W. Schuler Chairman, Stericycle, Inc. 4560 Horton Street, Emeryville, CA 94608
Pieter J. Strijkert, Ph.D. Chairman, IntroGene b.v., 4560 Horton Street, Emeryville, CA 94608
Chairman, Pharming b.v.,
Chairman, New Drug
Research Foundation
</TABLE>
<TABLE>
<CAPTION>
Executive Officers Title Business Address
------------------ ----- ----------------
<S> <C> <C>
William J. Rutter, Ph.D. Chairman 4560 Horton Street, Emeryville, CA 94608
Edward E. Penhoet, Ph.D. Vice Chairman 4560 Horton Street, Emeryville, CA 94608
Sean P. Lance President, Chief Executive 4560 Horton Street, Emeryville, CA 94608
Officer
Richard W. Barker, Ph.D. Senior Vice President 4560 Horton Street, Emeryville, CA 94608
Rajen K. Dalal Vice President, Corporate 4560 Horton Street, Emeryville, CA 94608
Development
Renato P. Fuchs, Ph.D. Senior Vice President, 4560 Horton Street, Emeryville, CA 94608
Manufacturing & Development
Operations
William G. Green, Esq. Senior Vice President, 4560 Horton Street, Emeryville, CA 94608
General Counsel & Secretary
David T. Kingsbury, Ph.D. Vice President, Chief 4560 Horton Street, Emeryville, CA 94608
Information Officer
James L. Knighton Vice President, Investor 4560 Horton Street, Emeryville, CA 94608
Relations
Magnus Lundberg Vice President, President 4560 Horton Street, Emeryville, CA 94608
Chiron Therapeutics &
Chiron Vaccines
Bernadita Mendez, Ph.D. Vice President, Regulatory 4560 Horton Street, Emeryville, CA 94608
& Quality Affairs
Philip K. Moody Vice President, Financial 4560 Horton Street, Emeryville, CA 94608
Operations
Linda W. Short Vice President, Human 4560 Horton Street, Emeryville, CA 94608
Resources
James R. Sulat Vice President, Chief 4560 Horton Street, Emeryville, CA 94608
Financial Officer
</TABLE>
Page 7 of 8 pages
<PAGE>
<TABLE>
<S> <C> <C>
Pablo D.T. Valenzuela, Ph.D. Senior Vice President 4560 Horton Street, Emeryville, CA 94608
Lewis T. Williams, MD, Ph.D. Chief Scientific Officer, 4560 Horton Street, Emeryville, CA 94608
Vice President, President
Chiron Technologies
</TABLE>
Page 8 of 8 pages
